000281853 001__ 281853
000281853 005__ 20251117103908.0
000281853 0247_ $$2doi$$a10.1007/s00415-025-13441-1
000281853 0247_ $$2pmid$$apmid:41186756
000281853 0247_ $$2ISSN$$a0367-004X
000281853 0247_ $$2ISSN$$a0012-1037
000281853 0247_ $$2ISSN$$a0340-5354
000281853 0247_ $$2ISSN$$a1432-1459
000281853 037__ $$aDZNE-2025-01226
000281853 041__ $$aEnglish
000281853 082__ $$a610
000281853 1001_ $$aNoli, B.$$b0
000281853 245__ $$aVGF AQEE- and GGEE-peptides differentiate between dementia types.
000281853 260__ $$a[Darmstadt]$$bSteinkopff$$c2025
000281853 3367_ $$2DRIVER$$aarticle
000281853 3367_ $$2DataCite$$aOutput Types/Journal article
000281853 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1763372232_17169
000281853 3367_ $$2BibTeX$$aARTICLE
000281853 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000281853 3367_ $$00$$2EndNote$$aJournal Article
000281853 520__ $$aAlzheimer's disease (AD) and dementia with Lewy bodies (DLB) are neurodegenerative disorders with overlapping clinical features, making differential diagnosis challenging. The AQEE and GGEE peptides, derived from the proVGF neuroprotein, have emerged as potential cerebrospinal fluid (CSF) biomarkers for dementia. Indeed, we previously observed a reduction in AQEE-10 levels using selected reaction monitoring (SRM) and GGEE levels using enzyme-linked immunosorbent assay (ELISA) in a cohort of DLB patients compared to both controls and AD patients. To better investigate the diagnostic utility of these peptides, we analyzed CSF samples from both the original cohort and a newly recruited cohort. The new cohort (cohort 1) included patients, from Ulm University Hospital, with Parkinson's disease dementia (PDD) and DLB (combined as PDD/DLB; n = 18), and AD (n = 19). The previously analyzed cohort (cohort 2), from the Amsterdam University Medical Center, included DLB (n = 44), AD (n = 20), and cognitively healthy controls (n = 22). AQEE-10 levels were quantified by multiple reaction monitoring (MRM) in cohort 1 and by ELISA in both cohorts. GGEE levels were measured by ELISA in cohort 1 to corroborate and extend previous findings. MRM-based analysis revealed a significant reduction of AQEE-10 levels in DLB compared to both controls and AD (p < 0.05; ROC-AUC: 78% and 82%, respectively). This finding was confirmed by ELISA, for both AQEE-10 and GGEE peptide levels, along with a positive correlation between their concentrations. These results support AQEE-10 and GGEE as promising peptide biomarkers for distinguishing DLB from other dementia.
000281853 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000281853 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000281853 650_7 $$2Other$$aAlzheimer´s disease
000281853 650_7 $$2Other$$aBiomarker
000281853 650_7 $$2Other$$aCerebrospinal fluid
000281853 650_7 $$2Other$$aLewy Body dementia
000281853 650_7 $$2Other$$aNeuroprotein
000281853 650_7 $$2Other$$aVGF
000281853 650_7 $$2NLM Chemicals$$aBiomarkers
000281853 650_7 $$2NLM Chemicals$$aVGF protein, human
000281853 650_7 $$2NLM Chemicals$$aNerve Growth Factors
000281853 650_2 $$2MeSH$$aHumans
000281853 650_2 $$2MeSH$$aMale
000281853 650_2 $$2MeSH$$aFemale
000281853 650_2 $$2MeSH$$aAged
000281853 650_2 $$2MeSH$$aLewy Body Disease: cerebrospinal fluid
000281853 650_2 $$2MeSH$$aLewy Body Disease: diagnosis
000281853 650_2 $$2MeSH$$aBiomarkers: cerebrospinal fluid
000281853 650_2 $$2MeSH$$aAlzheimer Disease: cerebrospinal fluid
000281853 650_2 $$2MeSH$$aAlzheimer Disease: diagnosis
000281853 650_2 $$2MeSH$$aAged, 80 and over
000281853 650_2 $$2MeSH$$aCohort Studies
000281853 650_2 $$2MeSH$$aParkinson Disease: cerebrospinal fluid
000281853 650_2 $$2MeSH$$aParkinson Disease: diagnosis
000281853 650_2 $$2MeSH$$aEnzyme-Linked Immunosorbent Assay
000281853 650_2 $$2MeSH$$aMiddle Aged
000281853 650_2 $$2MeSH$$aDementia: cerebrospinal fluid
000281853 650_2 $$2MeSH$$aDementia: diagnosis
000281853 650_2 $$2MeSH$$aDiagnosis, Differential
000281853 650_2 $$2MeSH$$aROC Curve
000281853 650_2 $$2MeSH$$aNerve Growth Factors
000281853 7001_ $$0P:(DE-2719)9001534$$aMuqaku, B.$$b1$$udzne
000281853 7001_ $$aGouda, M.$$b2
000281853 7001_ $$aManai, A. L.$$b3
000281853 7001_ $$aNagl, M.$$b4
000281853 7001_ $$aAnderl-Straub, S.$$b5
000281853 7001_ $$0P:(DE-HGF)0$$aWerner, L.$$b6
000281853 7001_ $$aOtto, M.$$b7
000281853 7001_ $$aTeunissen, C. E.$$b8
000281853 7001_ $$0P:(DE-2719)9001560$$aOeckl, P.$$b9$$udzne
000281853 7001_ $$00000-0003-3915-208X$$aCocco, C.$$b10
000281853 773__ $$0PERI:(DE-600)1421299-7$$a10.1007/s00415-025-13441-1$$gVol. 272, no. 11, p. 745$$n11$$p745$$tJournal of neurology$$v272$$x0367-004X$$y2025
000281853 8564_ $$uhttps://pub.dzne.de/record/281853/files/DZNE-2025-01226%20SUP.zip
000281853 8564_ $$uhttps://pub.dzne.de/record/281853/files/DZNE-2025-01226.pdf$$yOpenAccess
000281853 8564_ $$uhttps://pub.dzne.de/record/281853/files/DZNE-2025-01226.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000281853 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001534$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000281853 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001560$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b9$$kDZNE
000281853 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000281853 9141_ $$y2025
000281853 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-10
000281853 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-10
000281853 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-10
000281853 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-10
000281853 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-10
000281853 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000281853 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEUROL : 2022$$d2024-12-10
000281853 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-10
000281853 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-10$$wger
000281853 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-10
000281853 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-10
000281853 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-10
000281853 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ NEUROL : 2022$$d2024-12-10
000281853 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-10
000281853 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000281853 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-10$$wger
000281853 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-10
000281853 9201_ $$0I:(DE-2719)5000073$$kAG Öckl$$lTranslational Mass Spectrometry and Biomarker Research$$x0
000281853 980__ $$ajournal
000281853 980__ $$aVDB
000281853 980__ $$aUNRESTRICTED
000281853 980__ $$aI:(DE-2719)5000073
000281853 9801_ $$aFullTexts